ICON Public’s (ICLR) Buy Rating Reiterated at Truist Financial

Truist Financial reissued their buy rating on shares of ICON Public (NASDAQ:ICLR) in a report issued on Wednesday,Benzinga reports. They currently have a $284.00 price objective on the medical research company’s stock, down from their previous price objective of $295.00.

Other equities analysts have also issued reports about the stock. Robert W. Baird lowered their target price on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. The Goldman Sachs Group reduced their price objective on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Evercore ISI decreased their target price on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Barclays reduced their target price on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ICON Public has a consensus rating of “Moderate Buy” and an average price target of $289.10.

ICON Public Trading Up 1.4 %

NASDAQ:ICLR opened at $207.51 on Wednesday. The company has a 50-day moving average price of $226.98 and a 200-day moving average price of $283.77. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The stock has a market cap of $17.12 billion, a price-to-earnings ratio of 23.13, a P/E/G ratio of 1.57 and a beta of 1.21. ICON Public has a 12 month low of $183.38 and a 12 month high of $347.72.

ICON Public (NASDAQ:ICLR) last released its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.10 EPS. Equities analysts predict that ICON Public will post 13.42 EPS for the current year.

Hedge Funds Weigh In On ICON Public

Several large investors have recently added to or reduced their stakes in ICLR. Ashton Thomas Private Wealth LLC bought a new stake in shares of ICON Public during the 2nd quarter valued at $54,000. EverSource Wealth Advisors LLC lifted its stake in ICON Public by 39.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after purchasing an additional 111 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its stake in ICON Public by 119.6% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock worth $130,000 after acquiring an additional 226 shares during the last quarter. First Horizon Advisors Inc. raised its stake in ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares in the last quarter. Finally, Crestwood Advisors Group LLC purchased a new stake in ICON Public during the second quarter valued at approximately $288,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.